Closing Thoughts on Recent Data in GI Cancers From ESMO 2023

Commentary
Video

Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key gastrointestinal cancer data updates discussed following the 2023 ESMO Congress Meeting.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on practice-changing data in community practice.

      Subscribe Now!
      Recent Videos
      Site of Neuroendocrine Tumors Affects Outcomes With Cabozantinib
      Site of Neuroendocrine Tumors Affects Outcomes With Cabozantinib
      Targeted Therapy Options Sometimes Underutilized in Metastatic CRC
      Targeted Therapy Options Sometimes Underutilized in Metastatic CRC
      Pembrolizumab Combo Boosts Survival in HER2+ Gastric/GEJ Cancer
      Pembrolizumab Combo Boosts Survival in HER2+ Gastric/GEJ Cancer
      FDA Fully Approves Pembrolizumab/Trastuzumab Regimen in HER2+ Gastric Cancer
      FDA Fully Approves Pembrolizumab/Trastuzumab Regimen in HER2+ Gastric Cancer
      Efficacy and Safety Outcomes Support Approval of Cabozantinib in NETs
      Efficacy and Safety Outcomes Support Approval of Cabozantinib in NETs
      SUNLIGHT Findings Emphasize Role of VEGF Inhibition in Refractory CRC
      SUNLIGHT Findings Emphasize Role of VEGF Inhibition in Refractory CRC
      Tislelizumab Gains FDA Nod in Advanced Esophageal Cancer
      Tislelizumab Gains FDA Nod in Advanced Esophageal Cancer
      Experts Discuss Tislelizumab’s FDA Approval in Esophageal Cancer
      Experts Discuss Tislelizumab’s FDA Approval in Esophageal Cancer
      Next Steps for Evaluating Balstilimab Plus Botensilimab in MSS mCRC
      Next Steps for Evaluating Balstilimab Plus Botensilimab in MSS mCRC
      Targeted Therapy Options for Gastric/GEJ Cancers Expand
      Targeted Therapy Options for Gastric/GEJ Cancers Expand
      Related Content
      FDA Approves Nivolumab/Ipilimumab in First-Line Hepatocellular Cancer

      FDA Approves Nivolumab/Ipilimumab in First-Line Hepatocellular Cancer

      Jordyn Sava
      April 11th 2025
      Article

      Findings from the CheckMate 9DW trial support the FDA approval of nivolumab and ipilimumab in unresectable hepatocellular carcinoma

      Read More

      LaPelusa’s Journey in the Dynamic Field of GI Oncology

      LaPelusa’s Journey in the Dynamic Field of GI Oncology

      Jordyn Sava;Michael LaPelusa, MD
      May 1st 2024
      Podcast

      In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

      Listen

      Tovecimig Plus Paclitaxel Improves ORR in Advanced Biliary Tract Cancer

      Tovecimig Plus Paclitaxel Improves ORR in Advanced Biliary Tract Cancer

      Jordyn Sava
      April 4th 2025
      Article

      The primary end point of overall response rate has been met in the COMPANION-002 trial of tovecimig and paclitaxel in advanced biliary tract cancer.

      Read More

      Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

      Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

      Jordyn Sava;Arvind Dasari, MD, MS
      November 15th 2023
      Podcast

      In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

      Listen

      Neoadjuvant Tremelimumab/Durvalumab Combination Exhibits Antitumor Activity in G/GEJ Cancer

      Neoadjuvant Tremelimumab/Durvalumab Combination Exhibits Antitumor Activity in G/GEJ Cancer

      Tony Berberabe, MPH
      April 3rd 2025
      Article

      Neoadjuvant immunotherapy shows antitumor activity in mismatch repair deficient/MSI gastric/gastroesophageal junction adenocarcinoma.

      Read More

      Behind the FDA Approval: Cabozantinib for Advanced Neuroendocrine Tumors

      Behind the FDA Approval: Cabozantinib for Advanced Neuroendocrine Tumors

      Jonah Feldman
      April 2nd 2025
      Article

      Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

      Read More